Quality control on ultrasound for HAPIN trial

RNS Number : 0876H

Medaphor Group PLC

13 November 2018

 

MedaPhor Group plc 

("MedaPhor" or the "Company") 

MedaPhor provides quality control of fetal ultrasound images for the HAPIN trial

MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, announces it is working with the Household Air Pollution Intervention Network (HAPIN) trial to provide quality control of fetal ultrasound images. The work is led by principal investigators at Johns Hopkins, Emory and Colorado State Universities and is funded by The Bill & Melinda Gates Foundation and the National Institutes for Health (NIH).

The HAPIN study, currently taking place in Guatemala, India, Peru and Rwanda, is a randomised controlled trial to assess the effect of using of liquefied petroleum gas (LPG) stoves instead of customary cooking practices on air pollution, child health and adult chronic disease. The data is urgently needed to inform policies on the health gains that can be obtained by scaling up LPG stoves or other interventions to reduce household air pollution among vulnerable populations around the world.

As part of the trial, 3,200 pregnant women are being monitored using ultrasound to assess gestational age and fetal development. The HAPIN team is keen to ensure that the ultrasound images collected are of the highest quality, so has asked Medaphor to use its AI-based ScanNav image inspection algorithms and its panel of expert sonographers to do this.

Co-Principal Investigator Dr. William Checkley said: "We are delighted to have MedaPhor as part of our research team assisting us in obtaining the highest quality of fetal ultrasounds for this landmark study of household air pollution and health outcomes across the life span."

Nicholas Sleep, CTO at MedaPhor, said: "We are pleased to be helping the HAPIN project by using ScanNav to automate the quality assurance of the ultrasound images being taken in the field. We hope that this will help the HAPIN team ensure the validity of the study results."

MedaPhor Group plc		www.medaphor.com
Stuart Gall, CEO  Ian Whittaker, COO		Tel: [phone]
Cenkos Securities		Tel:  [phone]
Mark Connelly / Cameron MacRitchie (Nominated Advisor)
Michael Johnson / Julian Morse (Corporate Broking)
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy / Paul McManus	Mob: [phone] / Mob: [phone]

About MedaPhor (www.investors.medaphor.com)

MedaPhor (AIM: MED), the intelligent ultrasound software and simulation company, develops artificial intelligence-based clinical image analysis software tools, augmented reality-based needle guidance software and advanced hi-fidelity haptic and manikin-based training simulators for medical practitioners.

Based in Cardiff and Oxford in the UK, Atlanta in the US and Hong Kong in Asia, MedaPhor operates two divisions:

Intelligent Ultrasound Simulation Division 

Focuses on hi-fidelity ultrasound education and training through simulation.  Its three main products are the ScanTrainer OBGYN and General Medical simulator training platform, the HeartWorks echocardiography simulator platform and the BodyWorks Eve Point of Care and Emergency Medicine Simulator.  Over 500 MedaPhor simulators have been sold to over 300 medical institutions in over 30 countries around the world.

Intelligent Ultrasound Clinical Division 

Focuses on augmented reality and deep-learning based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav and NeedleGuide.   ScanNav uses machine-learning based algorithms to automatically identify, grade and capture good ultrasound images. NeedleGuide aims to simplify ultrasound-guided needling by using deep learning and augmented reality to provide the user with pathway guidance and automated tracking for a range of medical procedures.

Some products in the pipeline may require US FDA approval, as such this material should be considered informational only and does not constitute an offer to sell or infer claims or benefits.

 

END

 

 

NRAFFDFLEFASESF